The data show that Regorafenib is equivalent to TAS-102 in metastatic CRC.

Published Date: 08 Mar 2023

A real-world comparison showed similar overall survival in patients with refractory metastatic CRC treated with regorafenib or trifluridine/tipiracil (TAS-102).

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Universal screening approach achieves a comparable detection rate of lung cancer

2.

Living in a more pedestrian-friendly area may reduce the risk of cancer and obesity-related diseases.

3.

Advanced Solid Tumors May Benefit from Investigative Immunotherapy Combo.

4.

Researchers use AI to monitor side effects of chemotherapy and support families dealing with pediatric cancer.

5.

Loneliness and social isolation linked to heightened risk of death in those with cancer


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot